Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Yangling Li^{1

2}, Dongmei Zhou¹, Shuang Xu¹, Mingjun Rao³, Zuoyan Zhang⁴, Linwen Wu⁴, Chong Zhang⁴, Nengming Lin^{1

2

3}

Affiliations

¹ Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou 310006, China.
² Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
³ Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
⁴ School of Medicine, Zhejiang University City College, Hangzhou 310015, China.

Published Erratum

Yangling Li et al. Cancer Biol Med. 2022.

. 2022 May 10;19(7):1109-1110.

doi: 10.20892/j.issn.2095-3941.2022.0172.

Yangling Li^{1

2}, Dongmei Zhou¹, Shuang Xu¹, Mingjun Rao³, Zuoyan Zhang⁴, Linwen Wu⁴, Chong Zhang⁴, Nengming Lin^{1

2

3}

¹ Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou 310006, China.
² Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
³ Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
⁴ School of Medicine, Zhejiang University City College, Hangzhou 310015, China.

No abstract available

Figures

1. Li Y, Zhou D, Xu S, Rao M, Zhang Z, Wu L, et al. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors. Cancer Biol Med. 2020;17:387–400. - PMC - PubMed